SG Americas Securities LLC Has $220,000 Holdings in CorMedix Inc. (NASDAQ:CRMD)

SG Americas Securities LLC increased its position in shares of CorMedix Inc. (NASDAQ:CRMD) by 44.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,205 shares of the company’s stock after buying an additional 8,372 shares during the period. SG Americas Securities LLC’s holdings in CorMedix were worth $220,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CRMD. JPMorgan Chase & Co. increased its stake in shares of CorMedix by 685.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 194,108 shares of the company’s stock worth $1,568,000 after purchasing an additional 169,397 shares during the last quarter. State Street Corp increased its position in CorMedix by 0.8% during the third quarter. State Street Corp now owns 1,225,756 shares of the company’s stock worth $9,904,000 after buying an additional 10,204 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in CorMedix by 13.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,190 shares of the company’s stock valued at $100,000 after buying an additional 2,700 shares during the period. FMR LLC lifted its position in shares of CorMedix by 54.3% in the third quarter. FMR LLC now owns 4,618 shares of the company’s stock valued at $37,000 after buying an additional 1,625 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of CorMedix by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,284,464 shares of the company’s stock worth $10,380,000 after acquiring an additional 13,171 shares during the period. 34.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

CRMD has been the topic of a number of research analyst reports. D. Boral Capital restated a “buy” rating and issued a $15.00 price target on shares of CorMedix in a research note on Wednesday, January 22nd. Needham & Company LLC raised their target price on shares of CorMedix from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Truist Financial upped their price target on shares of CorMedix from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. StockNews.com upgraded shares of CorMedix to a “sell” rating in a research report on Friday, November 8th. Finally, Royal Bank of Canada upped their target price on CorMedix from $11.00 to $12.00 and gave the company an “outperform” rating in a research report on Thursday, December 19th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, CorMedix has a consensus rating of “Moderate Buy” and a consensus target price of $15.67.

Insider Activity

In related news, EVP Elizabeth Hurlburt sold 140,027 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $11.18, for a total value of $1,565,501.86. Following the sale, the executive vice president now owns 45,397 shares of the company’s stock, valued at $507,538.46. The trade was a 75.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 5.20% of the company’s stock.

CorMedix Price Performance

NASDAQ CRMD opened at $10.16 on Friday. CorMedix Inc. has a fifty-two week low of $2.89 and a fifty-two week high of $13.85. The business has a fifty day moving average price of $9.98 and a two-hundred day moving average price of $8.62. The stock has a market capitalization of $616.51 million, a PE ratio of -12.54 and a beta of 1.57.

CorMedix Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.